• Record: found
  • Abstract: found
  • Article: not found

Managing diabetes-related costs and quality of life issues: Value of insulin analogs and pens for inpatient use.


Health policy (Amsterdam, Netherlands)

Elsevier BV

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Diabetes mellitus is a serious disease that is growing at an epidemic rate, yet it can be managed and controlled with appropriate individualized therapy. In the hospital, costs can be reduced and health-related quality of life (HRQOL) improved by optimal glycemic and blood pressure control, minimal or no hypoglycemia, minimal glucose fluctuations, fewer or no complications, and a shorter length of stay. Insulin analogs and pens are tools that have been used successfully to manage hyperglycemia in the inpatient and outpatient settings. Limited evidence suggests that these advances in insulin therapy may increase HRQOL and improve cost-effectiveness in hospitalized patients compared with regular and NPH insulin and vial/syringe administration of insulin, although additional data are needed to confirm these findings. Most insulin algorithms used in hospitals rely on analogs for basal and prandial glucose control; however, analogs have not been extensively evaluated in clinical trials in this patient population. More studies are needed to evaluate the impact of insulin pen and analog use on HRQOL and costs in hospitalized patients.

      Related collections

      Author and article information

      [1 ] Experiential Education, Pharmacy Practice, Midwestern University Chicago College of Pharmacy, 555 W. 31st Street - AH 355, Downers Grove, IL 60515, United States.
      Health Policy
      Health policy (Amsterdam, Netherlands)
      Elsevier BV
      Aug 2010
      : 96
      : 3
      20226560 S0168-8510(10)00052-7 10.1016/j.healthpol.2010.02.006


      Comment on this article